Subclinical hypothyroidism (SCH) is defined as an asymptomatic state characterized by normal serum levels of free thyroxine and elevated serum concentrations of thyrotropin (> 4.0 μ U/ml). The association between SCH and type 2 diabetes has been well established. Proliferative diabetic retinopathy (PDR) that is characterized by neovascularization is a leading cause of visual loss in adults worldwide. However, whether SCH is related to PDR has not been studied. This study thus aimed to evaluate the relationship between SCH and PDR in type 2 diabetes. A total of 371 type 2 diabetic subjects were enrolled: 187 subjects with PDR and 184 subjects without diabetic retinopathy (with HbA1c above 6.5% and at least 10 years of diabetes duration). Subjects with PDR had higher blood pressure, higher serum levels of total cholesterol, low-density lipoprotein cholesterol and thyrotropin, and higher urinary albumin excretion rate. Of the 371 diabetics, 83 subjects (22.4%) were diagnosed as SCH (male 12.1% and female 29.9%). The prevalence of SCH in the PDR group (51/187, 27.3%) was higher than that in the subjects without diabetic retinopathy (32/184, 17.4%). Logistic regression analysis showed that after adjusting for compounding variables, SCH was independently related with PDR ( p = 0.032, adjusted OR = 2.485). These results indicate that type 2 diabetic patients with PDR are at an increased risk of SCH. A routine screening for thyroid function may thus be considered advisable in PDR subjects. This may be helpful in investigating new strategies preventing or treating PDR in clinical practice.
Subclinical hypothyroidism (SCH) is defined as an asymptomatic state characterized by a normal serum free thyroxine level and elevated serum concentration of thyrotropin (Helfand and Redfern 1998) . SCH is associated with atherogenic lipid profile (Bindels et al. 1999; Tsimihodimos et al. 1999; Pirich et al. 2000; Tzotzas et al. 2000; Vierhapper et al. 2000; Efstathiadou et al. 2001; Meier et al. 2001; Kanaya et al. 2002; Caraccio et al. 2002; Monzani et al. 2004) , impaired vascular function (Taddei et al. 2003) , impaired cardiac function, and increased risk for the development of atherosclerosis and myocardial dysfunction (Hak et al. 2000; Biondi et al. 2002) . With respect to the metabolic syndrome, as might be expected, the prevalence of SCH is higher in patients with metabolic conditions than that in non-metabolic syndrome subjects (Uzunlulu et al. 2007) . Recently, in a prospective cohort study, an association between SCH and an increased risk of coronary heart disease events and mortality was reported (Rodondi et al. 2010) .
The association between type 2 diabetes and SCH is well recognized, with reported prevalence of 2.2-17% (Feely and Isles 1979; Perros et al. 1995; Smithson 1998) . However, only a few studies have explored the effects of SCH in the diabetic population. Insulin resistance has been reported in SCH (Maratou et al. 2009 ). Further, it has been shown that small variations in thyrotropin might exert a marked effect on lipid levels in diabetic adults (Chubb et al. 2005) . Diabetic retinopathy (DR) is one of the most common microvascular complications. Common risk factors for the development of DR include duration of diabetes, poor glycemic control, elevated blood pressure, and dyslipide mia, of which the latter three are potentially amenable to therapeutic intervention (Stratton et al. 2001; Barnett et al. 2006 ). Whether SCH is related to DR in type 2 diabetic patients remains controversial. One study addressing this relationship was performed in 588 Taiwanese type 2 diabetic patients with SCH in comparison with euthyroid patients. In the cross-sectional analysis, SCH was associated with a higher frequency of nephropathy (after adjustment for, among other factors, age, sex and HbA 1C ), but not with an increased risk of DR (Chen et al. 2007 ). In another crosssectional study of 1,170 type 2 diabetic patients, patients with SCH had a higher prevalence of retinopathy, especially sight-threatening form, when compared with diabetic euthyroid subjects (Yang et al. 2010) .
Further, the thyroid hormone axis has an important role in the development of the retina and contributes to normal retinal vascular density. Experimental studies have shown that hypothyroidism is associated with preretinal neo vascula ri zation, and that systemic thyroxine supplementation is associated with changes in vessel density and area (Mookadam et al. 2004; Mutapcic et al. 2005) . DR can be classified as non-proliferative diabetic retinopathy and pro lifera tive diabetic retinopathy (PDR). Neovascularization is the principal hallmark of PDR. Neovascularization frequently leads to vitreous hemorrhage and retinal detachment in diabetic patients. Now PDR is a leading cause of visual loss in adults worldwide. To our knowledge there have, however, been no relevant studies to evaluate the relationship between SCH and PDR in type 2 diabetic subjects. To examine the relationship between PDR and SCH, a casecontrol study was carried out. Since the appearance of any DR usually occurs during the first ten years of diabetes, we selected diabetic patients without signs of DR with at least 10 years of diabetes duration as control subjects. Poor glucose control is an important factor in the development of PDR. Consequently, only control subjects with HbA1c above 6.5% were selected. PDR subjects with varying diabetic duration or HbA1c were selected as case subjects.
Subjects and Methods

Subjects
Recruiting patients started from January 2008 to December 2009. In this hospital-based case-control study, a total of 391 type 2 diabetic patients were selected. Two subjects with clinical hypothyroidism, and 18 with subclinical hyperthyroidism were later excluded. Accordingly, 371 patients were included in the case-control analysis (Fig. 1 ). For the case-control analysis, 187 patients with PDR were considered as case patients, while 184 patients with no diabetic retinopathy (NDR) whose HbA1c was above 6.5%, yet with at least 10 years of diabetic history were considered as control subjects. Patients with known thyroid diseases, hyperthyroidism, thyroidectomy, malignancy, pregnancy, or any acute intercurrent illness were also Fig. 1 . Selection of the patients for study.
PDR, proliferative diabetic retinopathy; DR, diabetic retinopathy; SCH, subclinical hypothyroidism 396 subjects were recruited. 391 patients had not known thyroid disorders. After tested thyroid function, only 371 type 2 diabetic subjects were included in the analysis.
excluded. This study was conducted in accordance with the declaration of Helsinki. The study was conducted with approval from the Ethics Committee of Beijing Tongren Hospital, Capital Medical University. Written informed consent was obtained from all participants. In this study, out of the PDR patients, 96.3% of the patients (n = 180) received insulin treatment, compared with 64.7% of the NDR patients (n = 119). However, in the NDR group, 45.1% of the patients (n = 83) were on metformin, compared with only 9.6% of the PDR patients (n = 18). The prevalence of taking acarbose was not significantly different between the PDR group (n = 74) and the NDR group (n = 91) (39.6% vs 49.5%, p > 0.05).
Clinical examination
Subjects' height and weight were measured while each subject was wearing indoor clothing without shoes. Body mass index (BMI) was calculated as weight divided by height squared. Blood pressure was measured in the sitting position after 10 minutes of rest. Fasting venous blood was collected for measurement of glucose, lipid profile, renal function and thyroid function. HbA1c was measured using high-performance liquid chromatography instruments (Variant, Bio-Rad Laboratories, U.S.A.) with a reference range of 4.0-6.0%. Urine albumin excretion rate (UAER) was measured in an overnight urine specimen using chemiluminescence (Immulite 1000, D.P.C., U.S.A.). Diabetic nephropathy (DN) was defined as UAER > 20 μ g/ min.
Thyroid function tests and definitions
Thyroid function was measured using chemiluminescent immunometric assay (Immulite 1000; DPC, USA). The reference range of serum thyrotropin (TSH) was 0.4-4.0 μ IU/ml, the reference range of free thyroxine was 10-23 pmol/L, and the reference range of free triiodothyronine was 2.3-6.3 pmol/L. SCH patients were defined as having TSH level ≥ 4.0 μ IU/ml under normal free thyroxine level conditions, and without taking any thyroid medication (thyroid hormone replacement or thyreostatic medication or iodine). Euthyroidism was defined as normal TSH and free thyroxine levels.
Diabetic retinopathy
All subjects were assessed using ophthalmoscopy and fundus photographs. Digital fundus photographs (2 eyes × 2 fields), taken using a TRC-NW7SF (Topcon Co. Tokyo, Japan) non-mydriatic camera at 45°, were examined independently by two qualified fundus photography graders following quality assurance protocols. A trained ophthalmologist performed fundus examination using ophthalmoscopy in all patients who were given tropicamide eye drops to dilate their pupils. The ophthalmologist was blinded to the disease status of the respective subjects except for the eye condition. The retinal status was classified as NDR, non-proliferative diabetic retinopathy or PDR. The severity of DR was graded on the basis of the eye with the worst condition.
Statistical analysis
Data were analyzed using SPSS 11.5 statistical software. Continuous variables were expressed as mean ± standard deviations. Serum levels of TSH, albumin, urea nitrogen, creatinine, and alanine aminotransferase (ALT) and UAER were expressed as median with range and analyzed using a non-parametric test. Nonparametric correlation analysis was utilized to analyse between TSH and other variables. Logistic regression analysis was used to analyze the association between PDR with SCH. The odds ratios (OR) and 95% Confidence intervals (CI) were calculated utilizing logistic regression analysis. A p-value < 0.05 on the two-tail was considered to indicate statistical significance.
Results
Clinical characteristics of the participants
The baseline characteristics of the 371 type 2 diabetic patients with NDR or PDR are given in Table 1 . Subjects with PDR had significantly higher blood pressure, higher serum levels of total cholesterol (TC), low-density lipoprotein cholesterol (LDL-c), urea nitrogen, creatinine and TSH, higher UAER and lower albumin ( p < 0.05). Of all PDR subjects, 57.8% subjects (108/187) had DN, higher percentage than that in the NDR group (46/184, 25.0%; p < 0.001).
Relationship between SCH and PDR
Of the 371 diabetic patients, SCH was newly diagnosed in 83 subjects. The overall prevalence of SCH was 22.4% (male 12.1% and female 29.9%, p < 0.001). The prevalence of SCH in the PDR group (51/187, 27.3%) was higher than that in the NDR group (32/184, 17.4%, p = 0.022).
All the subjects were further divided into no DN subgroup and DN subgroup based on their UAER level. Within the DN subgroup, the prevalence of SCH in the PDR group was higher than that in the NDR group (10.9% vs 29.6%, p < 0.05, Fig. 2 ). In the no-DN subgroup, the prevalence of SCH was not significantly different between the NDR and the PDR group. Within the NDR group, the difference in the prevalence of SCH was not significant between the DN subgroup and the no-DN subgroup. Similar results were found in the PDR group (Fig. 2) .
In the PDR group, TSH correlated positively with UAER (r = 0.176, p = 0.019) and serum creatinine (r = 0.181, p = 0.013). These correlations were not found in the NDR group. There was no correlation between TSH and serum albumin and ALT either in the PDR group or the NDR group ( p > 0.05).
NDR and PDR subjects were further divided into the euthyroid subgroup and the SCH subgroup. Within the PDR group, serum creatinine, TC and LDL-c in the SCH subgroup were higher than those in the euthyroid subgroup ( p < 0.05, Table 2 ). However, the differences in the serum creatinine, TC and LDL-c between the euthyroid subgroup and the SCH subgroup within the NDR group were not significant ( p > 0.05, Table 3 ).
In order to identify an independent relationship between SCH and PDR, logistic regression analysis was performed. The OR for SCH (1.781, p = 0.023) was amplified in type 2 diabetic patients with PDR (Table 4) . UAER was also found to be a risk factor for PDR (OR 1.010, Table 4 ). Logistic regression analysis testing for age, gender, HbA1c, systolic blood pressure, BMI, LDL-c, albumin, showed that SCH was independently associated PDR, proliferative diabetic retinopathy; NDR, non diabetic retinopathy; SCH, subclinical hypothyroidism; DN, diabetic nephropathy. slashed bar: no diabetic nephropathy, solid bar: diabetic nephropathy Within the NDR group or the PDR group, the difference in prevalence of SCH was not significant between the DN subgroup and the no-DN subgroup. All the subjects were further divided into no DN subgroup and DN subgroup based on their UAER level. Within the DN subgroup, the prevalence of SCH in the PDR and DN group was higher than that in the NDR and DN group. In the no DN subgroup, the prevalence of SCH was not significant between the NDR and the PDR group. with PDR (adjusted OR 2.682, Table 4 ). Further adjusted for UAER and serum creatinine, SCH was also correlated with PDR (adjusted OR 2.485, Table 4 ).
According to the National Academy of Clinical Biochemistry guidelines, all patients were classified as groups of TSH 0.35-2.5 μ IU/ml and TSH ≥ 2.5 μ IU/ml. Patients with TSH ≥ 2.5 μ IU/ml had a significantly higher rate of PDR than patients with TSH of 0.35-2.5 μ IU/ml [57.5% (84/146) vs 45.8% (103/225), p = 0.027].
Discussion
In this study of type 2 diabetic adults, PDR was found to be related with a higher prevalence of SCH (after adjustment for, among other variables, gender, age and HbA1c). Although PDR subjects had a higher prevalence of DN, and UAER appeared to be an independent risk factor for PDR in our study, SCH was found to be associated with PDR after further adjusting for UAER and serum creatinine.
As we know, DR and DN are two of the most critical microvascular complications in diabetes. Further, the mechanisms of developing these two complications are similar and manifold. It was reported earlier that SCH was associated with a higher prevalence of nephropathy in a hospitalbased study (Chen et al. 2007 ) and patients with proteinuria had higher TSH levels (Gilles et al. 2008 ). In our study, people with PDR had a higher prevalence of DN. To eliminate the effect of DN on the prevalence of SCH, all the subjects were further divided into the no DN group and the DN group. We found that PDR subjects had higher prevalence of SCH both in the no DN group and the DN group. However, within either the NDR or the PDR group, there was no significant difference in terms of prevalence of SCH between the no DN group and the DN group. In the logistic regression analysis, SCH was found to be associated with PDR after further adjusting for UAER and serum creatinine. These results indicated that the association between SCH and PDR could not be fully explained by the higher prevalence of DN in PDR people. This may also indicate that the mechanisms involving the higher SCH prevalence in PDR patients may be different from those in DN patients.
Thyroid function contributes to normal retinal vascular density. Further, hypothyroidism can play a permissive role in the development of retinal neovascularization. Infants born very prematurely (27 weeks) were more likely to have low thyroxine levels, indicating an abnormal function of the hypothalamus-pituitary-thyroid axis (Kirsten 2000; Beeram and Wilson 2000) . Premature infants with low serum thyroxine (hypothyroxinemia) were at risk for retinopathy of prematurity (Fisher 1990 ). In addition, hypothyroidism increased permeability of retinal vessels in rats (Tilton et al. 1989) . It has been reported that methimazole-induced hypothyroidism neonatal rats were associated with preretinal neovascularization and reduced retinal vascular areas (Mookadam et al. 2004) . Similarly, Berkowitz et al. (2004) reported exacerbation of oxygen-induced retinopathy in neonatal rats exposed to methylimidazole. These considerations raised the possibility that hypothyroidism may be involved in the formation of retinal neo vasculari zation.
Our present data revealed that the prevalence of SCH was 12.1% in males and 29.9% in females with type 2 diabetes. Perros et al. (1995) found that the prevalence of SCH was 3.3% in men and 4.6% in women with type 2 diabetes. NHANES III, a population study, reported that the prevalence of SCH was 3.4% in males and 5.8% in females (Hollowell et al. 2002) . The prevalence of SCH in our study was greater than those reported in the two previous studies. This may be explained by the difference of subjects selected in the different studies, as only subjects with PDR or NDR were eligible for this study. SCH was more prevalent in women than in men in this study. This is supported by results from previous research studies (Perros et al. 1995; Canaris et al. 2000; Hollowell et al. 2002) . Screening thyroid function has been recommended only in children and adolescents with type 1 diabetes (A.D.A. 2008) . With regards to type 2 diabetic adults, there is no consensus as to whether screening for thyroid disorders should be mandatory. Further studies are needed to evaluate whether it is necessary to screen thyroid function in type 2 diabetes with microvascular complications.
A definition of a normal TSH reference range has been subjected to considerable debate. This reference range is critical for diagnosing subclinical thyroid dysfunction. Some clinicians have advocated reducing the upper limit of the normal reference for TSH to 2.5 μ IU/ml or 3.0 μ IU/ml. The new National Academy of Clinical Biochemistry (NACB) guidelines state that "greater than 95% of healthy, euthyroid subjects have a serum TSH concentration between 0.4 and 2.5 μ IU/ml" (Baloch et al. 2003) . In this study, the group with TSH ≥ 2.5 μ IU/ml showed a higher rate of PDR. Therefore, diabetic patients with TSH over 2.5 μ IU/ml should be warranted to be followed up.
To our knowledge there have been no relevant studies to evaluate the relationship between SCH and PDR in type 2 diabetic subjects. However, our study was of observational nature, and it is thus not advised to definitely conclude that treatment of SCH will reduce the risk for DR. Thyroxine replacement in patients with TSH within 4-10 μ IU/ml is still controversial (Helfand 2004) . In an experimental study, systemic thyroxine supplementation at 1 ug/g per day affected retinal vascular development in neonatal animals (Mutapcic et al. 2005) . However, it is still not known whether thyroxine replacement in diabetic patients will prevent DR. To demonstrate such a benefit would require a large clinical trial with a long follow-up period.
In summary, SCH is common in type 2 diabetic adults. Type 2 diabetic patients with PDR were at increased risk of SCH in this study. Additional studies should be carried out to determine whether this association can be confirmed in other prospective studies. Studies investigating the necessity of SCH screening and the potential treatment of SCH in diabetic patients are also needed. Further investigation is also warranted to assess whether SCH causes and/or worsens pre-existing retinopathy.
